I'm not sure timeline comparisons will be all that useful, as DNDN was then first to develop this type of cancer treatment, so it took the market a long time to realise the full value of DNDN. But now that DNDN has paved a way for others with a similar cancer treatment methodology to follow, I think the market is beginning to factor in value to PRR at an earlier stage in product development than was the case with DNDN.
In short, I think we are seeing a re-rating in process, and the recent SP run has a while to go yet before we get to a new base.
I'm not a scientist and this is just my laymans understanding of the difference between DNDN and PRR. Happy to be corrected.
DYOR, V5
prr v dndn, page-5
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $443.6M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 31.8¢ | 30.3¢ | $1.189M | 3.864M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 78803 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 1155 | 1 |
View Market Depth
| Last trade - 16.10pm 17/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |